Labrynix's founding design partner is Gene Matrix AI — a CLIA-certified genetic lab run by the same founder. It wasn't designed from theory; it was built from the operational reality of running genetic testing every day.
Gene Matrix AI runs real pharmacogenomics, hereditary-cancer, and preventive-genomics testing for clients across multiple countries. Every constraint Labrynix is built around — CLIA/CAP expectations, chain-of-custody, turnaround pressure, payer denials — is one this lab lives daily.
Like most genetic labs, the operation was stitched together: a LIS here, a separate reporting tool there, billing somewhere else, integrations cobbled together, and report assembly done by hand. Data was re-keyed between systems, denials slipped through, and reporting was slow and rigid.
Labrynix was built to replace that stack with one system where data captured once flows everywhere — operations, reporting, and billing — with a lab-trained AI layer (running on leading models) that drafts SOPs, workflows, and specialty reports. The lab always validates, approves, and signs out. AI never makes the clinical decision.
One operational core instead of five tools; branded, AI-drafted reports reviewed and signed out by qualified staff; billing visibility instead of handing claims into a black box; and integrations treated as core, not one-off projects — so the lab can scale without adding headcount for every new connection.
Named case studies from additional labs are on the way as we partner with our first customers — each published only with the lab's written permission and real, verifiable outcomes. We don't invent metrics.
We didn't start as a software company — we started in the lab. Labrynix is the platform we wished we'd had: one connected system for operations, reporting, and billing, with AI that does the busywork while our team keeps control of every clinical decision.
The scenarios below show how genetic and molecular labs would use Labrynix, using real product capabilities. They are not case studies of named customers, and the outcomes are directional — your results depend on your payers, processes, and validation. We don't invent metrics.
A pharmacogenomics lab assembles every report by hand — pulling gene–drug interactions, phenotype calls, and CPIC/FDA guidance into a template, then chasing Z-codes and prior-auth separately. Turnaround is slow, and molecular denials quietly pile up.
Labrynix LIMS runs the sample-to-report workflow; the lab-trained AI drafts each branded PGx report across 700+ medications (cardiac, psychiatric, diabetic, and more) informed by CPIC, FDA labeling, and PharmGKB; Billing keeps the Z-code, prior-auth, and medical-necessity documentation on the same record as the order.
What changes: report drafting moves from hours of manual assembly to AI-drafted minutes that qualified staff review and sign out; claims go out clean with the Z-code attached; and denials surface early instead of after they're lost.
An NGS / molecular lab tracks samples in spreadsheets, with QC scattered across instrument exports and no clean lineage from a sequencing library back to the original specimen. Errors are caught late, and audits are painful.
Labrynix LIMS tracks samples at the tube, plate, well, and run level with parent–child lineage through extractions and libraries; QC checkpoints gate each step with a recorded decision; Connect captures instrument output and run-level QC where integrated.
What changes: every result traces back to a specific specimen and position; QC is enforced at each step instead of reconstructed later; and the audit trail is inspection-ready instead of assembled by hand.
Early labs help shape the platform — and get hands-on implementation and support.
